A Phase I/II study of AZD4512 in relapsed/refractory B-cell acute lymphoblastic leukemia

Recruiting Phase 1,Phase 2 NCT07109219

Study Description

A study testing a new cancer drug called AZD4512 alone or with other treatments in teens and adults with B-cell leukemia that has returned or stopped responding to treatment

Study Details

Registry ID:: NCT07109219
Conditions:: B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase:: Phase 1,Phase 2
Target Enrollment:: 83 participants
Start Date:: November 12, 2025
Age Range:: 12–999 years
Healthy Volunteers:: No

Study Locations (26 sites)

Research Site
SalamancaSpain, Spain
Research Site
BarcelonaSpain, Spain
Research Site
Badalona(Barcelona)Spain, Spain
Research Site
SantanderSpain, Spain
Research Site
LondonUnited Kingdom, United Kingdom
Research Site
BloomsburyUnited Kingdom, United Kingdom
Research Site
ManchesterUnited Kingdom, United Kingdom
Research Site
Toronto, OntarioCanada, Canada
Research Site
Franklin, TennesseeUnited States, United States
Research Site
Nashville, TennesseeUnited States, United States
Research Site
Chicago, IllinoisUnited States, United States
Research Site
Houston, TexasUnited States, United States
Research Site
Iowa City, IowaUnited States, United States
Research Site
GuangzhouChina, China
Research Site
Duarte, CaliforniaUnited States, United States
Research Site
TaichungTaiwan, Taiwan
Research Site
TianjinChina, China
Research Site
TaipeiTaiwan, Taiwan
Research Site
Taipei CityTaiwan, Taiwan
Research Site
SeoulKorea, Republic of, Korea, Republic of
Research Site
SeoulSouth Korea, South Korea
Research Site
Vancouver, British ColumbiaCanada, Canada
Research Site
ChūōkuJapan, Japan
Research Site
Bunkyō CityJapan, Japan
Research Site
Bunkyo-kuJapan, Japan
Research Site
MelbourneAustralia, Australia

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →